Related Experiment Video
Updated: Aug 14, 2026

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
Published on: March 17, 2014
Burkholderia cepacia in cystic fibrosis. Variable disease course
D D Frangolias1, E Mahenthiralingam, S Rae
1Pulmonary Research Laboratory, Division of Infectious and Immunological Diseases, Department of Pediatrics, Canadian HIV Trials Network, British Columbia, Vancouver.
Abstract:
Variable clinical course has been reported with the acquisition of Burkholderia cepacia in patients who have cystic fibrosis (CF). We hypothesized that the perceived worsening with B. cepacia may reflect the underlying severity of pulmonary disease at the time of acquisition. To test this hypothesis, we matched CF patients colonized with B. cepacia with CF patients not colonized with the organism. Two-year pre- and postacquisition data and long-term data were compared. Patients were matched for gender, age (+/- 1 yr), height (+/- 5 cm), weight (+/- 8 kg), percent predicted forced expiratory volume in one second (% pred FEV(1)) (+/- 10%), and pancreatic sufficiency status. Differences in rates of change pre- and postacquisition for FEV(1), FVC, weight, and frequency of intravenous courses were compared within pairs with the Wilcoxon signed rank test. Two-year and long-term survival was compared within pairs with the McNemar test. No significant differences were observed in mean annual rates of change in weight (0.33 and -0.28 kg/yr), % pred FEV(1) (-0.36 and -1.74%/yr), and percent predicted forced vital capacity (% pred FVC) (-3.80 and -2.32%/yr) between B. cepacia and control pairs in 2-yr and long-term postacquisition interval, respectively. Similar rates of change were noted for pre- to postacquisition intervals within pairs for weight (0.17 kg/yr), % pred FEV(1) (-0.16%/yr), % pred FVC (5.02 %/yr). There was a significantly higher rate of intravenous antibiotic courses in B. cepacia cases in the 2-yr and long-term postacquisition interval. Higher mortality was observed in the B. cepacia cases in the long term (p < 0.05). We conclude that colonization with B. cepacia does not necessarily adversely affect pulmonary status, but is associated with reduced long term survival. Whereas previous associations may be attributed to a propensity to colonize those who had more advanced disease, specific strain types of B. cepacia may have enhanced pathogenicity.
Insights
Burkholderia cepacia (B. cepacia) colonization in cystic fibrosis (CF) patients does not always worsen lung function. However, B. cepacia is linked to increased intravenous antibiotic use and reduced long-term survival in CF patients.
Area of Science:
- Medical Microbiology
- Pulmonology
- Genetics
Background:
- Burkholderia cepacia complex (BCC) infections in cystic fibrosis (CF) patients are associated with variable clinical outcomes.
- Previous studies suggest BCC acquisition leads to accelerated clinical deterioration.
Purpose of the Study:
- To determine if B. cepacia acquisition impacts pulmonary disease progression in CF patients.
- To investigate the association between B. cepacia colonization and clinical outcomes, controlling for baseline disease severity.
Main Methods:
- Matched cohort study comparing CF patients colonized with B. cepacia to non-colonized controls.
- Patients were matched for age, sex, BMI, FEV1, and pancreatic status.
- Analysis of pre- and post-acquisition pulmonary function (FEV1, FVC), weight changes, and intravenous antibiotic courses.
Main Results:
- No significant differences in annual rates of change for FEV1, FVC, or weight were observed between B. cepacia and control groups.
- B. cepacia cases showed a significantly higher frequency of intravenous antibiotic courses.
- Higher long-term mortality was observed in the B. cepacia cohort (p < 0.05).
Conclusions:
- B. cepacia colonization itself may not directly worsen pulmonary status in CF.
- The association of B. cepacia with poorer outcomes may be due to patients with more advanced disease being more susceptible to colonization.
- Specific B. cepacia strains might possess enhanced pathogenicity, contributing to worse clinical trajectories.
Related Concept Videos
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Cryptococcal Meningitis
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

